DISPOSITION AND METABOLISM OF F6-1α,25(OH)2 VITAMIN D3 AND 1α,25(OH)2 VITAMIN D3 IN THE PARATHYROID GLANDS OF RATS DOSED WITH TRITIUM-LABELED COMPOUNDS

Publisher Website
Google Scholar
Abstract
26,26,26,27,27,27-Hexafluoro-1α,25(OH)2 vitamin D3, a hexafluorinated analog of 1α,25(OH)2 vitamin D3, has been reported to be several times more potent than the parent compound with respect to some vitamin D actions. The reason for enhanced biological activity in the bones, kidneys, and small intestine appears to be related to F6-1α,25(OH)2 vitamin D3 metabolism to ST-232 (26,26,26,27,27,27-hexafluoro-1α,23S,25-trihydroxyvitamin D3), a bioactive 23S-hydroxylated form that is resistant to further metabolism. We compared the disposition and metabolism of [1β-3H]F6-1α,25(OH)2 vitamin D3 and [1β-3H]1α,25(OH)2 vitamin D3 in parathyroid glands of rats intravenously administered with labeled compounds at a dose of 10 μg/kg. In the [1β-3H]F6-1α,25(OH)2 vitamin D3-dosed group, radioactivity was highly detected in the kidneys, parathyroid glands, and the small intestine. The radioactivity in the parathyroid glands remained high until 48 h postdosing, with values of 2.5, 8.4, and 14.6 times higher at 6, 24, and 48 h postdosing than after dosing with [1β-3H] 1α,25(OH)2 vitamin D3. In the group given [1β-3H]F6-1α,25(OH)2 vitamin D3, the unchanged compound was mainly detected with a small amount of ST-232 at 6 h postdosing. At the 24- and 48-h time points, over half of the radioactivity was observed as ST-232, and additionally, ST-233, the 23-oxo form, accounted for a small amount at the 48-h time point. The present study demonstrated local retention of [1β-3H]F6-1α,25(OH)2 vitamin D3 and the bioactive metabolite ST-232 in parathyroid glands after intravenous administration. The findings may indicate one of the reasons for the higher potency of F6-1α,25(OH)2 vitamin D3 than 1α,25(OH)2 vitamin D3 in parathyroid.

This publication has 29 references indexed in Scilit: